🚀 VC round data is live in beta, check it out!
Cardiol Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cardiol Therapeutics and similar public comparables like Dimerix, Kotra Industries, Heidelberg Pharma, Starpharma and more.
Cardiol Therapeutics Overview
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Founded
2017
HQ
Employees
22
Website
Sectors
Financials (LTM)
EV
$136M
Cardiol Therapeutics Financials
Cardiol Therapeutics reported last 12-month revenue of —.
In the same LTM period, Cardiol Therapeutics generated — in gross profit and had net loss of ($24M).
Revenue (LTM)
Cardiol Therapeutics P&L
In the most recent fiscal year, Cardiol Therapeutics reported revenue of — and EBITDA of ($25M).
Cardiol Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($25M) | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($24M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cardiol Therapeutics Stock Performance
Cardiol Therapeutics has current market cap of $152M, and enterprise value of $136M.
Market Cap Evolution
Cardiol Therapeutics' stock price is $1.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $136M | $152M | 5.6% | XXX | XXX | XXX | $-0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCardiol Therapeutics Valuation Multiples
Cardiol Therapeutics trades at (5.5x) EV/EBITDA.
EV / Revenue (LTM)
Cardiol Therapeutics Financial Valuation Multiples
As of April 11, 2026, Cardiol Therapeutics has market cap of $152M and EV of $136M.
Equity research analysts estimate Cardiol Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cardiol Therapeutics has a P/E ratio of (6.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $152M | XXX | $152M | XXX | XXX | XXX |
| EV (current) | $136M | XXX | $136M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/EBIT | (5.6x) | XXX | (5.5x) | XXX | XXX | XXX |
| P/E | (6.3x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cardiol Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cardiol Therapeutics Margins & Growth Rates
Cardiol Therapeutics' revenue in the last fiscal year grew by —.
Cardiol Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Cardiol Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (31%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cardiol Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dimerix | XXX | XXX | XXX | XXX | XXX | XXX |
| Kotra Industries | XXX | XXX | XXX | XXX | XXX | XXX |
| Heidelberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Curatis Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cardiol Therapeutics M&A Activity
Cardiol Therapeutics acquired XXX companies to date.
Last acquisition by Cardiol Therapeutics was on XXXXXXXX, XXXXX. Cardiol Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cardiol Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCardiol Therapeutics Investment Activity
Cardiol Therapeutics invested in XXX companies to date.
Cardiol Therapeutics made its latest investment on XXXXXXXX, XXXXX. Cardiol Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cardiol Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cardiol Therapeutics
| When was Cardiol Therapeutics founded? | Cardiol Therapeutics was founded in 2017. |
| Where is Cardiol Therapeutics headquartered? | Cardiol Therapeutics is headquartered in Canada. |
| How many employees does Cardiol Therapeutics have? | As of today, Cardiol Therapeutics has over 22 employees. |
| Who is the CEO of Cardiol Therapeutics? | Cardiol Therapeutics' CEO is David G. Elsley. |
| Is Cardiol Therapeutics publicly listed? | Yes, Cardiol Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Cardiol Therapeutics? | Cardiol Therapeutics trades under CRDL ticker. |
| When did Cardiol Therapeutics go public? | Cardiol Therapeutics went public in 2019. |
| Who are competitors of Cardiol Therapeutics? | Cardiol Therapeutics main competitors are Dimerix, Kotra Industries, Heidelberg Pharma, Starpharma. |
| What is the current market cap of Cardiol Therapeutics? | Cardiol Therapeutics' current market cap is $152M. |
| Is Cardiol Therapeutics profitable? | No, Cardiol Therapeutics is not profitable. |
| What is the current net income of Cardiol Therapeutics? | Cardiol Therapeutics' last 12 months net income is ($24M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.